Companies/Ligand Pharmaceuticals Incorporated

Company profile

Ligand Pharmaceuticals Incorporated

NASDAQ: LGND · Healthcare · Biotechnology

PublicHQ Jupiter, CACIK 0000886163Reports USD

#258 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

80B+

FH 87DQ 79GM 59SS 81

v0.1 · 65/100 weight · provisional

↑ net margin, listing tenure · ↓ growth stability, workforce scale

Methodology →

Revenue TTM

$274.5M

Rev growth YoY (TTM)

+51.2%

Net income (FY)

$124.5M

Employees

Market cap

$6.4B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$268.1M$268.1M2025

Net income$124.5M$124.5M2025

Operating income$41.0M$41.0M2025

Total assets$1.6B$1.6B2025

Liabilities$543.4M$543.4M2025

Equity$1.0B$1.0B2025

Revenue trend

FY2021 – FY2025 · USD

$277.1M

FY21

$36.5M

FY22

$50.1M

FY22

$59.2M

FY22

$196.2M

FY22

$131.3M

FY23

$167.1M

FY24

$268.1M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Royalty33%

Intangible Royalty Assets27%

Contract Revenue14%

Material Sales, Captisol, Core8%

Royalty, Kyprolis7%

Financial Royalty Assets6%

By geography

Not disclosed.

The read

Ligand Pharmaceuticals Incorporated booked $268.1M in FY2025 revenue, growing 60% year over year — faster than most Healthcare companies we track, at a 46.4% net margin.

Peers · Healthcare

Chemed Corporation89A Mirum Pharmaceuticals, Inc.64C Hinge Health, Inc.47D Scholar Rock Holding Corporation38D

Key facts

CEOTodd C. Davis

SectorHealthcare

IndustryBiotechnology

HeadquartersJupiter, CA

ExchangeNASDAQ: LGND

Employees68

IPO date1992-11-18

Latest filings

8-K2026-06-25 8-K2026-06-22 8-K2026-06-09 8-K2026-05-18 10-Q2026-05-08 8-K2026-05-07 8-K2026-04-30 8-K2026-04-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.